Relapse of aggressive and disruptive behavior in mentally retarded adults following antipsychotic drug withdrawal predicts psychotropic drug use a decade later

Journal of Clinical Psychiatry

Volumn 67, Issue 8, 2006, Pages 1272-1277

  Janowsky, David S ^a,b   Barnhill, L Jarrett ^a,b   Khalid, Abdul S ^b   Davis, John M ^c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b Murdoch Center   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT;

ADULT; AGED; AGGRESSION; ARTICLE; CONTROLLED STUDY; DISRUPTIVE BEHAVIOR; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALADJUSTMENT; MALE; MENTAL DEFICIENCY; PRIORITY JOURNAL; RELAPSE;

EID: 33748964787     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v67n0815     Document Type: Article

References (26)

1. Janowsky DS, Barnhill LJ, Davis JM. Olanzapine for self-injurious, aggressive, and disruptive behavior in intellectually disabled adults: a retrospective, open-label, naturalistic trial. J Clin Psychiatry 2003;64:1258-1265
2. Cohen SA, Underwood MT. The use of clozapine in a mentally retarded and aggressive population. J Clin Psychiatry 1994;55:440-444
3. McDougle CJ, Holmes JP, Bronson MR, et al. Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. J Am Acad Child Adolesc Psychiatry 1997;36:685-693
4. McDougle CJ, Kem DL, Posey DJ. Case series: use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry 2002;41:921-927
5. Aman MG. Patterns of drug use, methodological consideration, measurement, technique and future trends. In: Aman M, Singh N, eds. Psychopharmacology and Developmental Disabilities. Berlin, Germany: Springer-Verlag; 1989:1-28
6. Stoiker JJ, Koedoot PJ, Heerdink ER, et al. Psychotropic drug use in intellectually disabled group-home residents with behavioral problems. Pharmacopsychiatry 2002;35:19-23
7. Kiernan C, Reeves D, Alborz A. The use of anti-psychotic drugs with adults with learning disabilities and challenging behaviour. J Intellect Disabil Res 1995;39(pt 4):263-274
8. Branford D, Collacott RA, Thorp C. The prescribing of neuroleptic drugs for people with learning disabilities living in Leicestershire. J Intellect Disabil Res 1995;39(pt 6):495-500
9. Branford D. A review of antipsychotic drugs prescribed for people with learning disabilities who live in Leicestershire. J Intellect Disabil Res 1996;40(pt 4):358-368
10. Clarke DJ, Kelley S, Thinn K, et al. Psychotropic drugs and mental retardation, 1: disabilities and the prescription of drugs for behaviour and for epilepsy in three residential settings. J Ment Defic Res 1990;34:385-395
11. Baumeister AA, Sevin JA, King BH. Neuroleptics. In: Reiss S, Aman MG, eds. Psychotropic Medications and Developmental Disabilities: The International Consensus Handbook. Columbus, Ohio: The Ohio State University Nisonger Center; 1998:133-149
12. Gualtieri CT, Quade D, Hicks R, et al. Tardive dyskinesia and other clinical consequences of neuroleptic treatment in children and adolescents. Am J Psychiatry 1984;141:20-23
13. Rao JM, Cowie VA, Mathew B. Tardive dyskinesia in neuroleptic medicated mentally handicapped subjects. Acta Psychiatr Scand 1987;76:507-513
14. Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry 2002;14:59-64
15. Kalachnik JE, Leventhal BB, James DH, et al. Guidelines for the use of psychotropic medication. In: Reiss S, Aman MG, eds. Psychotropic Medications and Developmental Disabilities: The International Consensus Handbook. Columbus, Ohio: The Ohio State Nisonger Center; 1998:45-72
16. May P, London EB, Zimmerman T, et al. A study of the clinical outcome of patients with profound mental retardation gradually withdrawn from chronic neuroleptic medication. Ann Clin Psychiatry 1995;7:155-160
17. Wressell SE, Tyrer SP, Berney TP. Reduction in antipsychotic drug dosage in mentally handicapped patients: a hospital study. Br J Psychiatry 1990;157:101-106
18. Zahir A, Fraser W, Kerr MP, et al. Reducing antipsychotic medication in people with a learning disability. Br J Psychiatry 2000;174:42-46
19. Spreat S, Serafin C, Behar D, et al. Tranquilizer reduction trials in a residential program for persons with mental retardation. Hosp Community Psychiatry 1993;44:1100-1102
20. Ahmed Z, Fraser W, Kerr MP, et al. Reducing antipsychotic medication in people with a learning disability. Br J Psychiatry 2000;176:42-46
21. Branford D. Factors associated with the successful or unsuccessful withdrawal of antipsychotic drug therapy prescribed for people with learning disabilities. J Intellect Disabil Res 1996;40(pt 4):322-329
22. Briggs R. Monitoring and evaluating psychotropic drug use for persons with mental retardation: a follow up report. Am J Ment Retard 1989;6:633-639
23. Heistad GT, Zimmerman RI, Doebler MI. Long term usefulness of thioridazine for institutionalized mentally retarded patients. Am J Ment Defic 1982;87:243-254
24. Janowsky DS, Barnhill LJ, Shetty M, et al. Minimally effective doses of conventional antipsychoptic medications used to treat aggression, self-injurious and destructive behaviors in mentally retarded adults. J Clin Psychopharmacol 2005;25:1-7
25. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223
26. Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol 2004;24:192-208